-Caveat Lector-

>From http://www.freep.com/news/health/nstaph12_20021112.htm

Germs develop a deadly defense

Drug-resistant bacteria discovered in Detroit

November 12, 2002

BY EMILIA ASKARI
FREE PRESS STAFF WRITER

A 40-year-old Detroit area woman had endured painfully infected foot sores for more 
than
a year.

Doctors gave her numerous antibiotics, but nothing worked. Finally, last April, they
amputated one of her toes -- and made a frightening discovery.

Her sores were infected with a virulent new strain of the bacterium staphylococcus 
aureus,
or staph aureus. By stealing genetic material from another bug, the new strain became
totally resistant to vancomycin, the longtime drug of last defense against it. Health 
officials
would not identify the metro Detroit woman or what hospital treated her.

The infection was the first of its kind in the world and a landmark defeat for doctors 
and
public health officials in the fight against growing antibiotic resistance. It also 
was evidence
that the Detroit area has become an incubator for resistant strains.

"From a scientific point of view, it's probably one of the most remarkable and 
significant
events in my lifetime," said Dr. Steve Lerner, vice chief of infectious diseases at 
Detroit
Medical Center.

Added Dr. Fred Tenover of the federal Centers for Disease Control and Prevention in
Atlanta: "This is an organism that could cause very serious disease if it was in the
community."

Staph aureus is a common pathogen that infects about 400,000 U.S. hospital patients a
year. About one-quarter of them die. For decades, scientists have been dreading -- but
expecting -- a staph aureus strain to emerge that is resistant to vancomycin.

Some experts postulate that eventually, so many bacteria will develop resistance that
antibiotics won't work and hospitals will be filled with people dying from infections, 
as they
were in the 1920s.

Staph aureus can live innocuously in the nose of a healthy person. About 5 to 10 
percent of
Michiganders have it and don't know it, said William Brown, a Wayne State University
pathology professor. If it infects the blood, however, it can quickly become fatal, 
particularly
if the person has another medical condition.

In the 1920s, British scientist Alexander Fleming discovered penicillin, the first 
antibiotic
developed from mold. By the mid-1950s, about a decade after penicillin came into wide
use, most staph aureus strains in this country were resistant to it. So the 
pharmaceutical
industry came up with methicillin and a series of related drugs.

Also developed in the late 1950s, vancomycin had a lot of side effects and was not 
widely
used. Methicillin and its kin were much more popular -- and the bacteria soon began
growing resistant to them.

That was especially true in the Detroit area, where many intravenous drug users in the
1970s began mixing antibiotics, including methicillin, with heroin. It was a misguided
attempt to avoid infection from dirty needles, said Dr. Marcus Zervos, an infectious 
disease
physician at Beaumont Hospital in Royal Oak.

The primary effect: a rapidly increasing methicillin resistance in the metro area.
Subsequently, the resistant bacteria infected hospital patients and others who didn't 
use
illicit drugs.

"Since our part of the country overused vancomycin compared to other areas, that's why
we saw this problem with staph aureus," Zervos said.

For years, some physicians held out hope that vancomycin was a super drug, one that
would never be outsmarted by bugs. The first indication that staph aureus was becoming
resistant to vancomycin came in 1997 in Japan, a country known in medical circles for 
its
liberal use of antibiotics. Vancomycin still could kill the strain discovered there -- 
but only at
a much larger dosage. Later that year, the world's second case of staph aureus with 
partial
resistance to vancomycin was found at Oakwood Hospital in Dearborn.

"We're the capital of staph aureus resistance," Lerner, with the Detroit Medical 
Center,
said.

The bacteria causing the Detroit area woman's infection this year was even more 
virulent.
The emergence of a vancomycin-resistant strain has medical experts concerned that the
number of U.S. patients who die from infections may soon exceed 100,000 a year.

"In the scheme of public health threats, this has to rank close to the top," David 
Ropeik,
director of risk communication at the Harvard Center for Risk Analysis, said of 
antibiotic
resistance. "It's a serious threat now, and it's getting worse fast. It's dramatically 
more of a
public health threat than pesticides on food."

To combat resistance and ensure drugs work when needed, health officials want people to
do without antibiotics when infections are not life- threatening, said Matt Boulton,
Michigan's state epidemiologist.

"We have to change consumer attitudes," he said. "There should not always be an
expectation that you'll leave the doctor's office with antibiotics."

Aggressively keeping patients with resistant infections in isolation has helped several
Scandinavian countries slow antibiotic resistance dramatically. Doctors there also 
prescribe
the drugs only in extreme circumstances.

Many health professionals hope that following this summer's discovery of vancomycin-
resistant staph aureus in the metro woman's foot, Americans will be scared enough to
accept limited use of antibiotics.

So far, however, the public remains largely unaware of the discovery that shook doctors
around the world.

Brown, the WSU professor who also directs the microbiology lab at the Detroit Medical
Center, vividly remembers the June morning a technologist informed him of the strange 
test
results. A doctor caring for a woman at an outpatient dialysis clinic had sent in a 
swab with
a sample of pus from a sore where a catheter punctured the woman's skin. It looked like
staph aureus, but it was showing strong resistance to vancomycin.

"I figured it was a mistake," Brown recalled. So he took the suspect bacteria to a 
special
room used for handling the most dangerous microbes. There, he tested the bacteria for
vancomycin resistance and again got an off- the-chart reading.

That's when Brown got on the phone -- fast. He knew that he had to work quickly to keep
the bacteria from spreading. "I thought, 'Oh my God. This is it,' " he recalled.

Within two weeks, a team from the CDC in Atlanta had flown in and identified 400 
people in
the Detroit area who needed to be tested for signs of the rogue bacteria: hospital 
workers
and patients, members of the woman's choir and women who had gone to the same nail
salon as the woman.

So far, 300 more Michiganders have been tested, and no one else has been found to have
the vancomycin-resistant staph aureus, which doctors call VRSA (pronounced VER-sa).
Even though the bacteria causing the woman's infection were not killed by vancomycin, 
they
did respond in the laboratory to three other drugs. Two are antibiotics introduced 
within the
past two years. The other, an older drug, was given to the woman for three weeks.

Since then, the woman's infections have mostly healed and tests show no sign of VRSA in
her body. Doctors expect to continue to test her for months.

The antibiotics that worked against the woman's staph aureus infection have several
downsides, including a cost of more than $100 a day. And they're not a silver bullet 
either:
Other strains of staph aureus already have become resistant to them.

In September, a second case of vancomycin- resistant staph aureus was discovered in a
Pennsylvania patient who appears to be recovering.

But with two such incidents in three months, the medical profession is on high alert. 
Around
the world, experts are watching for the next VRSA and fervently hoping they will be 
able to
stop it.

>From the Kalamazoo labs of drugmaker Pharmacia, Vice President Ferdinand Massari said
it's harder to find new drugs. It takes at least a decade and $100 million to try, he 
said.

"For every one drug that you see in the store, there are probably 10,000 that were 
tested
and didn't make it," he said.

Contact EMILIA ASKARI at 313-223-4461 or [EMAIL PROTECTED]
~~~~~~~~~~~~~~~
A<>E<>R
+ + + + + + + + + + + + + + + + + + + + + + + + + + + + + +
Forwarded as information only; I don't believe everything I read or send
(but that doesn't stop me from considering it; obviously SOMEBODY thinks it's 
important)
+ + + + + + + + + + + + + + + + + + + + + + + + + + + + + +
In accordance with Title 17 U.S.C. section 107, this material is distributed without 
charge or
profit to those who have expressed a prior interest in receiving this type of 
information for
non-profit research and educational purposes only.
+ + + + + + + + + + + + + + + + + + + + + + + + + + + + + +
+ + + + + + + + + + + + + + + + + + + + + + + + + + + +
"Always do sober what you said you'd do drunk. That will teach you to keep your mouth
shut."
--- Ernest Hemingway

<A HREF="http://www.ctrl.org/";>www.ctrl.org</A>
DECLARATION & DISCLAIMER
==========
CTRL is a discussion & informational exchange list. Proselytizing propagandic
screeds are unwelcomed. Substance�not soap-boxing�please!  These are
sordid matters and 'conspiracy theory'�with its many half-truths, mis-
directions and outright frauds�is used politically by different groups with
major and minor effects spread throughout the spectrum of time and thought.
That being said, CTRLgives no endorsement to the validity of posts, and
always suggests to readers; be wary of what you read. CTRL gives no
credence to Holocaust denial and nazi's need not apply.

Let us please be civil and as always, Caveat Lector.
========================================================================
Archives Available at:
http://peach.ease.lsoft.com/archives/ctrl.html
 <A HREF="http://peach.ease.lsoft.com/archives/ctrl.html";>Archives of
[EMAIL PROTECTED]</A>

http://archive.jab.org/ctrl@;listserv.aol.com/
 <A HREF="http://archive.jab.org/ctrl@;listserv.aol.com/">ctrl</A>
========================================================================
To subscribe to Conspiracy Theory Research List[CTRL] send email:
SUBSCRIBE CTRL [to:] [EMAIL PROTECTED]

To UNsubscribe to Conspiracy Theory Research List[CTRL] send email:
SIGNOFF CTRL [to:] [EMAIL PROTECTED]

Om

Reply via email to